Earnings
CBIO
5.80
+1.93%
0.11
Currencies: USD
Items
Net Income
Depreciation and Amortization
Deferred Tax
Unamortized Expenditures
Accrued Expenses
Share-based Compensation
Assets Disposal
Financial Expenses
Investment Loss
Working Capital Change
Other Items
Operating Activities
Purchases of Fixed Assets
Proceeds from Disposal of Fixed Assets
Investment Expenditure
Investment Income
Other Investing Activities
Investing Activities
Issuance of Capital Stock
Issuance of Bonds
Proceeds from Borrowings
Dividend Payments
Repayment of Borrowings
Buyback Payments
Stock Incentive Compensation
Other Financing Activities
Financing Activities
Effect of Exchange Rate Changes 
Net Increase in Cash,Cash Equivalents
FY 2019-12-31
-55.18M
146.00K
--
--
--
--
3.20M
--
--
8.21M
--
-43.61M
-64.00K
--
--
--
27.46M
27.39M
327.00K
0.00
--
--
--
--
--
--
327.00K
--
-15.89M
FY 2018-12-31
-30.05M
149.00K
--
--
--
--
2.72M
--
--
-1.37M
--
-28.55M
-376.00K
--
--
--
-70.94M
-71.32M
116.41M
-5.08M
--
--
--
--
--
--
111.33M
--
11.46M
FY 2017-12-31
-21.56M
173.00K
--
--
--
--
881.00K
--
--
567.00K
--
-19.94M
-23.00K
--
--
--
-11.17M
-11.20M
35.40M
-14.32M
--
--
--
--
--
--
21.08M
--
-10.05M
FY 2016-12-31
-16.95M
389.00K
--
--
--
--
-2.75M
--
--
836.00K
--
-18.47M
-468.00K
--
--
--
-840.00K
-1.31M
958.00K
-10.00K
--
--
--
--
--
--
948.00K
--
-18.83M
FY 2015-12-31
-14.76M
470.00K
--
--
--
--
1.43M
--
--
-6.26M
--
-19.12M
-272.00K
--
--
--
37.63M
37.36M
-69.00K
9.38M
--
--
--
--
--
--
9.31M
--
27.55M

FY: Financial Year. It represents annual report.

Q: Quarter Report. Q1、Q2、Q3、Q4 represent three-month periodic financial reports.

Check out CBIO latest annual and quarterly financial reports. There are also historical financial reports for you to reference. You can analyze Catalyst Biosciences recent business situations by check its cash flow statements, balance sheets, income statements and other tables. Comprehensive data may help you to understand and analyze CBIO development prospects in various aspects, and this information may help you to better grasp the Catalyst Biosciences operation.